


# High-Throughput Screening Methods in Toxicity Testing



EDITED BY  
PABLO STEINBERG

WILEY


# HIGH-THROUGHPUT SCREENING METHODS IN TOXICITY TESTING

---

Edited by

**PABLO STEINBERG**

Institute for Food Toxicology and Analytical Chemistry  
University of Veterinary Medicine Hannover  
Hannover, Germany



**WILEY**

Copyright © 2013 by John Wiley & Sons, Inc. All rights reserved.

Published by John Wiley & Sons, Inc., Hoboken, New Jersey.  
Published simultaneously in Canada.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at [www.copyright.com](http://www.copyright.com). Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at <http://www.wiley.com/go/permission>.

**Limit of Liability/Disclaimer of Warranty:** While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at [www.wiley.com](http://www.wiley.com).

***Library of Congress Cataloging-in-Publication Data:***

High-throughput screening methods in toxicity testing / edited by Pablo Steinberg.  
pages cm  
Includes index.  
ISBN 978-1-118-06563-1 (hardback)  
1. High throughput screening (Drug development) 2. Toxicity testing.  
I. Steinberg, Pablo, editor if compilation.  
RS419.5.H542 2013  
615.1'9-dc23

2012035755

Printed in the United States of America

ISBN: 9781118065631

10 9 8 7 6 5 4 3 2 1

**HIGH-THROUGHPUT  
SCREENING METHODS  
IN TOXICITY TESTING**

# PREFACE

Conventional approaches to toxicity testing of chemicals and drugs are often decades old, costly, do not allow high-throughput testing, and are of questionable value when wanting to estimate human risk. The publication of the document entitled “Toxicity Testing in the 21st Century: A Vision and Strategy” by the US National Research Council and the implementation of the European legislation on the Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) have led to a paradigm shift regarding the strategy to be pursued when evaluating the toxic potential of chemicals and drugs. Namely, toxicity evaluation should be preponderantly performed by using high-throughput *in vitro* methods and toxicity testing methods in animals should play, if at all, a minimal role.

The book gives an overview on a variety of high-throughput screening methods being used in toxicity testing nowadays and should be of help to all scientists working in the field of toxicity evaluation and risk assessment of chemicals and drugs in chemico-pharmaceutical as well as biotechnology companies, contract laboratories, academia as well as regulatory agencies. The book chapters are written in such a way that they lend support to those wanting to establish these methods in their laboratories as well as those having to evaluate the data generated. Each chapter describes the principle of the method and includes detailed information on data generation, data analysis, and the use/application(s) in risk assessment. Moreover, the chapters not only list the advantages of the high-throughput method over the “conventional” methods used up to now in safety evaluation of chemicals and drugs but also point out limitations and pitfalls.

The book is divided into five parts. Part I includes the strategies pursued nowadays to predict the toxicity potential of chemicals and drugs through high-throughput bioactivity profiling, the incorporation of human dosimetry and exposure data into

high-throughput *in vitro* toxicity screening, and the use of human embryonic stem cells in high-throughput toxicity assays. Part II presents a variety of high-throughput assays to assess different cytotoxicity endpoints; Part III describes high-throughput assays to assess DNA damage and carcinogenesis; Part IV includes high-throughput assays to assess reproductive toxicity, cardiotoxicity, and hematotoxicity; and Part V presents high-throughput assays to assess drug metabolism and receptor-related toxicity. By including all these above-mentioned aspects, the book should be of great value to toxicologists, pharmacologists, analytical chemists, and pharmaceutical scientists working in academic institutions, industry, and regulatory agencies that are involved in safety evaluation and risk assessment of chemicals and drugs and an excellent complement to the current literature on toxicology in general and safety evaluation/risk assessment in particular. Because of the test systems and the toxicity endpoints described, this book could also be extremely interesting for all scientists working in the fields of biochemistry, cell biology, molecular biology, systems biology, and computational toxicology.

I hereby would like to thank all authors for their excellent contributions. Only because of them it was possible to conceive a book including such a broad spectrum of toxicity testing methods. The development of high-throughput methods to screen the toxic potential of drugs and chemicals is a rapidly evolving field. If the one or the other method was missed, then this omission was not on purpose and an incentive to actualize this version of the book in the future.

PABLO STEINBERG

# CONTRIBUTORS

**Harrie T. Besselink**, BioDetection Systems BV, Amsterdam, The Netherlands

**Jörg Blümel**, MedImmune, Gaithersburg, MD, USA

**Abraham Brouwer**, BioDetection Systems BV, Amsterdam, The Netherlands, and Department of Animal Ecology, VU University Amsterdam, Amsterdam, The Netherlands

**Bart van der Burg**, BioDetection Systems BV, Amsterdam, The Netherlands

**Alexander Bürkle**, Molecular Toxicology Group, Department of Biology, University of Konstanz, Konstanz, Germany

**Nathan J. Evans**, Research Department, Promega Corporation, Madison, WI, USA

**Francesca de Giorgi**, FluoFarma, Pessac, France

**Caroline Haglund**, Division of Clinical Pharmacology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden

**Bram Herpers**, Division of Toxicology, The Leiden Amsterdam Center for Drug Research, Leiden University, Leiden, The Netherlands

**Martin Höglund**, Division of Hematology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden

**G. Jean Horbach**, Department of Toxicology and Drug Disposition, Merck Sharp & Dohme, Oss, The Netherlands

**Keith A. Houck**, National Center for Computational Toxicology, Office of Research and Development, US Environmental Protection Agency, Research Triangle Park, NC, USA

**Xin Huang**, Cardiovascular Institute, Clinical Research Center, 2nd Affiliated Hospital at School of Medicine, Zhejiang University, Hangzhou, People's Republic of China

**François Ichas**, FluoFarma, Pessac, France

**Esther de Jong**, Laboratory for Health Protection Research, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands, and Institute for Risk Assessment Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands

**Lydia Jonker**, BioDetection Systems BV, Amsterdam, The Netherlands

**Richard S. Judson**, National Center for Computational Toxicology, Office of Research and Development, US Environmental Protection Agency, Research Triangle Park, NC, USA

**Min Jung Kim**, College of Pharmacy, Seoul National University, Seoul, South Korea

**Nadine Krause**, Nonclinical Safety, Merz Pharmaceuticals GmbH, Frankfurt (Main), Germany

**Rolf Larsson**, Division of Clinical Pharmacology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden

**Sander van der Linden**, BioDetection Systems BV, Amsterdam, The Netherlands

**Yi-jia Lou**, Institute of Pharmacology, Toxicology and Biochemical Pharmaceutics, Zhejiang University, Hangzhou, People's Republic of China

**Hai-yen Man**, BioDetection Systems BV, Amsterdam, The Netherlands

**Carl-Fredrik Mandenius**, Division of Biotechnology, Department of Physics, Chemistry and Biology, Linköping University, Linköping, Sweden

**Matthew T. Martin**, National Center for Computational Toxicology, Office of Research and Development, US Environmental Protection Agency, Research Triangle Park, NC, USA

**Thomas Meyer**, Multi Channel Systems GmbH, Reutlingen, Germany

**Richard A. Moravec**, Research Department, Promega Corporation, Madison, WI, USA

**María Moreno-Villanueva**, Molecular Toxicology Group, Department of Biology, University of Konstanz, Konstanz, Germany

**Andreas Natsch**, Givaudan Schweiz AG, Duebendorf, Switzerland

**Andrew L. Niles**, Research Department, Promega Corporation, Madison, WI, USA



**Satomi Onoue**, Department of Pharmacokinetics and Pharmacodynamics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan

**Stephanie Padilla**, Integrated Systems Toxicology Division, US Environmental Protection Agency, Research Triangle Park, NC, USA

**Kamala Pant**, BioReliance Corporation, Rockville, MD, USA

**Aldert H. Piersma**, Laboratory for Health Protection Research, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands, and Institute for Risk Assessment Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands

**Johanna Rajasärkkä**, Department of Food and Environmental Sciences, University of Helsinki, Helsinki, Finland

**David M. Reif**, National Center for Computational Toxicology, Office of Research and Development, US Environmental Protection Agency, Research Triangle Park, NC, USA

**Ann M. Richard**, National Center for Computational Toxicology, Office of Research and Development, US Environmental Protection Agency, Research Triangle Park, NC, USA

**Terry L. Riss**, Research Department, Promega Corporation, Madison, WI, USA

**Joshua F. Robinson**, Laboratory for Health Protection Research, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands, and Department of Toxicogenomics, Maastricht University, Maastricht, The Netherlands

**James F. Rusling**, Department of Chemistry, University of Connecticut, Storrs, CT, USA, and Department of Cell Biology, University of Connecticut Health Center, Farmington, CT, USA

**Ayako Sakai**, Laboratory of Cell Carcinogenesis, Division of Alternative Toxicology Test, Hatano Research Institute, Food and Drug Safety Center, Hadano, Kanagawa, Japan

**Kiyoshi Sasaki**, Laboratory of Cell Carcinogenesis, Division of Alternative Toxicology Test, Hatano Research Institute, Food and Drug Safety Center, Hadano, Kanagawa, Japan

**John Schenkman**, Department of Cell Biology, University of Connecticut Health Center, Farmington, CT, USA

**Willem G.E.J. Schoonen**, Department of Toxicology and Drug Disposition, Merck Sharp & Dohme, Oss, The Netherlands

**Michael Schwarz**, Department of Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Tübingen, Tübingen, Germany

**Yoshiki Seto**, Department of Pharmacokinetics and Pharmacodynamics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan

**Jonathan Z. Sexton**, Biomanufacturing Research Institute and Technology Enterprise, North Carolina Central University, Durham, NC, USA

**Imran Shah**, National Center for Computational Toxicology, Office of Research and Development, US Environmental Protection Agency, Research Triangle Park, NC, USA

**Joon Myong Song**, College of Pharmacy, Seoul National University, Seoul, South Korea

**André Stang**, Institut für Biologie und Umweltwissenschaften, Carl von Ossietzky Universität Oldenburg, Oldenburg, Germany

**Pablo Steinberg**, Institute for Food Toxicology and Analytical Chemistry, University of Veterinary Medicine Hannover, Hannover, Germany

**Joe C.R. Stevenson**, Department of Toxicology and Drug Disposition, Merck Sharp & Dohme, The Netherlands

**David M. Stresser**, Corning Gentest<sup>SM</sup> Contract Research Services, Corning Life Sciences - Discovery Labware, Woburn, MA, USA

**Noriho Tanaka**, Laboratory of Cell Carcinogenesis, Division of Alternative Toxicology Test, Hatano Research Institute, Food and Drug Safety Center, Hadano, Kanagawa, Japan

**Peter T. Theunissen**, Laboratory for Health Protection Research, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands, and Department of Toxicogenomics, Maastricht University, Maastricht, The Netherlands

**Russell S. Thomas**, The Hamner Institutes for Health Sciences, Research Triangle Park, NC, USA

**Frederik Uibel**, Department of Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Tübingen, Tübingen, Germany

**Luc Verschaeve**, Scientific Institute of Public Health, Operational Direction Public Health & Surveillance, Laboratory of Toxicology, Brussels, Belgium

**Marko Virta**, Department of Food and Environmental Sciences, University of Helsinki, Helsinki, Finland

**Barbara van Vugt-Lussenburg**, BioDetection Systems BV, Amsterdam, The Netherlands

**Beppy van de Waart**, Department of *In Vitro* & Environmental Toxicology, WIL Research, DD 's-Hertogenbosch, The Netherlands

**Bob van de Water**, Division of Toxicology, The Leiden Amsterdam Center for Drug Research, Leiden University, The Netherlands

**Femke M. van de Water**, Department of Toxicology and Drug Disposition, Merck Sharp & Dohme, Oss, The Netherlands

**Walter M.A. Westerink**, Department of In Vitro and Environmental Toxicology, WIL Research, DD's-Hertogenbosch, The Netherlands

**Barbara A. Wetmore**, The Hamner Institutes for Health Sciences, Research Triangle Park, NC, USA

**Kevin P. Williams**, Biomanufacturing Research Institute and Technology Enterprise, North Carolina Central University, Durham, NC, USA

**Roos Winter**, BioDetection Systems BV, Amsterdam, The Netherlands

**Irene Witte**, Institut für Biologie und Umweltwissenschaften, Carl von Ossietzky Universität Oldenburg, Oldenburg, Germany

**Tracy J. Worzella**, Research Department, Promega Corporation, Madison, WI, USA

**Shizuo Yamada**, Department of Pharmacokinetics and Pharmacodynamics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan

**George Zhang**, Corning Gentest<sup>SM</sup> Contract Research Services, Corning Life Sciences – Discovery Labware, Woburn, MA, USA

**Dan-yan Zhu**, Institute of Pharmacology, Toxicology and Biochemical Pharmaceutics, Zhejiang University, Hangzhou, People's Republic of China

# CONTENTS

|   |           |
|---|-----------|
| <b>PREFACE</b>  | <b>ix</b> |
| <b>CONTRIBUTORS</b>   | <b>xi</b> |
| <br><b>PART I GENERAL ASPECTS</b>   |           |
| <b>1 ToxCast: Predicting Toxicity Potential Through High-Throughput Bioactivity Profiling</b>                                       | <b>3</b>  |
| <i>Keith A. Houck, Ann M. Richard, Richard S. Judson, Matthew T. Martin, David M. Reif, and Imran Shah</i>                          |           |
| <b>2 High-Throughput Toxicity Testing in Drug Development: Aims, Strategies, and Novel Trends</b>                                   | <b>33</b> |
| <i>Willem G.E.J. Schoonen, Walter M.A. Westerink, Femke M. van de Water, and Horbach G. Jean</i>                                    |           |
| <b>3 Incorporating Human Dosimetry and Exposure Information with High-Throughput Screening Data in Chemical Toxicity Assessment</b> | <b>77</b> |
| <i>Barbara A. Wetmore and Russell S. Thomas</i>   |           |
| <b>4 The Use of Human Embryonic Stem Cells in High-Throughput Toxicity Assays</b>   | <b>97</b> |
| <i>Xin Huang, Dan-yan Zhu, and Yi-jia Lou</i>   |           |
|   | <b>v</b>  |

## PART II HIGH-THROUGHPUT ASSAYS TO ASSESS DIFFERENT CYTOTOXICITY ENDPOINTS

- 5 High-Throughput Screening Assays for the Assessment of Cytotoxicity**  
*Andrew L. Niles, Richard A. Moravec, Tracy J. Worzella, Nathan J. Evans, and Terry L. Riss*

109
- 6 High-Throughput Flow Cytometry Analysis of Apoptosis**  
*Francesca de Giorgi and François Ichas*

129
- 7 High Content Imaging-Based Screening for Cellular Toxicity Pathways**  
*Bram Herpers and Bob van de Water*

143
- 8 The Keratinosens Assay: A High-Throughput Screening Assay to Assess Chemical Skin Sensitization**  
*Andreas Natsch*

159
- 9 High-Throughput Screening Assays to Assess Chemical Phototoxicity**  
*Satomi Onoue, Yoshiki Seto, and Shizuo Yamada*

177

## PART III HIGH-THROUGHPUT ASSAYS TO ASSESS DNA DAMAGE AND CARCINOGENESIS

- 10 Ames II<sup>TM</sup> and Ames Liquid Format Mutagenicity Screening Assays**  
*Kamala Pant*

193
- 11 High-Throughput Bacterial Mutagenicity Testing: Vitotox<sup>TM</sup> Assay**  
*Luc Verschaeve*

213
- 12 Genotoxicity and Carcinogenicity: Regulatory and Novel Test Methods**  
*Walter M.A. Westerink, Joe C.R. Stevenson, G. Jean Horbach, Femke M. van de Water, Beppy van de Waart, and Willem G.E.J. Schoonen*

233
- 13 High-Throughput Genotoxicity Testing: The Greenscreen Assay**  
*Jörg Blümel and Nadine Krause*

271
- 14 High-Throughput Assays to Quantify the Formation of DNA Strand Breaks**  
*María Moreno-Villanueva and Alexander Bürkle*

285

|   |  |            |
|---|--|------------|
| <b>15</b>   | <b>High-Throughput Versions of the Comet Assay</b>   | <b>295</b> |
|   | <i>Irene Witte and André Stang</i>   |            |
| <b>16</b>   | <b>Automated Soft Agar Colony Formation Assay for the High-Throughput Screening of Malignant Cell Transformation</b>                                 | <b>309</b> |
|   | <i>Pablo Steinberg</i>   |            |
| <b>17</b>   | <b>High-Throughput Quantification of Morphologically Transformed Foci in Bhas 42 Cells (v-Ha-ras Transfected BALB/c 3T3) Using Spectrophotometry</b> | <b>317</b> |
|   | <i>Kiyoshi Sasaki, Ayako Sakai, and Noriho Tanaka</i>  |            |
| <br><b>PART IV    HIGH-THROUGHPUT ASSAYS TO ASSESS<br/>REPRODUCTIVE TOXICITY, CARDIOTOXICITY,<br/>AND HAEMATOTOXICITY</b> |  |            |
| <b>18</b>   | <b>ReProGlo: A New Stem-Cell-Based High-Throughput Assay to Predict the Embryotoxic Potential of Chemicals</b>                                       | <b>343</b> |
|   | <i>Frederik Uibel and Michael Schwarz</i>  |            |
| <b>19</b>   | <b>Embryonic Stem Cell Test (EST): Molecular Endpoints Toward High-Throughput Analysis of Chemical Embryotoxic Potential</b>                         | <b>357</b> |
|   | <i>Peter T. Theunissen, Esther de Jong, Joshua F. Robinson,<br/>and Aldert H. Piersma</i>  |            |
| <b>20</b>   | <b>Zebrafish Development: High-Throughput Test Systems to Assess Developmental Toxicity</b>  | <b>371</b> |
|   | <i>Stephanie Padilla</i>   |            |
| <b>21</b>   | <b>Single Cell Imaging Cytometry-Based High-Throughput Analysis of Drug-Induced Cardiotoxicity</b>   | <b>385</b> |
|   | <i>Min Jung Kim and Joon Myong Song</i>  |            |
| <b>22</b>   | <b>High-Throughput Screening Assays to Evaluate the Cardiotoxic Potential of Drugs</b>   | <b>403</b> |
|   | <i>Carl-Fredrik Mandenius and Thomas Meyer</i>   |            |
| <b>23</b>   | <b>High-Throughput Screening Assays to Evaluate the Hematotoxic Potential of Drugs</b>   | <b>421</b> |
|   | <i>Caroline Haglund, Rolf Larsson, and Martin Höglund</i>  |            |

**PART V HIGH-THROUGHPUT ASSAYS TO ASSESS DRUG  
METABOLISM AND RECEPTOR-RELATED TOXICITY**

- 24 High-Throughput Enzyme Biocolloid Systems for Drug Metabolism and Genotoxicity Profiling Using LC–MS/MS 433**  
*James F. Rusling and John Schenkman*
- 25 Higher-Throughput Screening Methods to Identify Cytochrome P450 Inhibitors and Inducers: Current Applications and Practice 453**  
*David M. Stresser and George Zhang*
- 26 High-Throughput Yeast-Based Assays to Study Receptor-Mediated Toxicity 479**  
*Johanna Rajasärkkä and Marko Virta*
- 27 Evaluating the Peroxisomal Phenotype in High Content Toxicity Profiling 501**  
*Jonathan Z. Sexton and Kevin P. Williams*
- 28 A Panel of Quantitative Calux® Reporter Gene Assays for Reliable High-Throughput Toxicity Screening of Chemicals and Complex Mixtures 519**  
*Bart van der Burg, Sander van der Linden, Hai-yen Man, Roos Winter, Lydia Jonker, Barbara van Vugt-Lussenburg, and Abraham Brouwer*
- 29 DR-Calux®: A High-Throughput Screening Assay for the Detection of Dioxin and Dioxin-Like Compounds in Food and Feed 533**  
*Barbara van Vugt-Lussenburg, Harrie T. Besselink, Bart van der Burg, and Abraham Brouwer*
- INDEX 547**

## **PART I**

---

### **GENERAL ASPECTS**



